As per the agreement, Bristol-Myers will transfer the manufacture and distribution of its atazanavir sulfate 200 mg and 300 mg capsules to Brazilian Ministry of Health’s technical-scientific unit of Fundação Oswaldo Cruz (Fiocruz) – Farmanguinhos.
Bristol-Myers Squibb president Mark Pavao said the company’s technology transfer agreement will ensure a sustainable supply of atazanavir in the future for the many patients who can benefit from the therapy in Brazil.
"The agreement also provides an opportunity to increase access to this medicine and supports the Brazilian government’s interests in the further development of its local pharmaceutical manufacturing base," Pavao said.